跳至主要内容
临床试验/NCT03592251
NCT03592251已完成不适用

Efficacy Evaluation of 26 Weeks' Dietary Supplementation With DHA- and EPA-enriched Oils on Memory Consolidation in Healthy Adults

Northumbria University2 个研究点 分布在 1 个国家目标入组 168 人开始时间: 2017年8月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
168
试验地点
2
主要终点
Computerised Location Learning task

研究概览

简要总结

The purpose of this study is to investigate the effects of EPA- and DHA-enriched omega-3 polyunsaturated fatty acid dietary supplements on overnight verbal and visual memory consolidation as well as morning alertness before and after 26 weeks of supplementation

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
25 Years 至 49 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Aged 25 to 49 years inclusive
  • Males and females
  • Self-report of good health

排除标准

  • English is not first language (some of the cognitive tasks have only been validated in native English speakers)
  • Habitual consumption of oily fish exceeds one fish meal per week
  • Habitual consumption of n-3 dietary supplements in the previous 6 months
  • Habitual use of dietary supplements within the last month (defined as more than 3 consecutive days or 4 days in total; some supplements that do not impact upon cognitive function e.g. garlic, protein, calcium are allowed. Please check with the research team if you are unsure)
  • Are a smoker or consume any nicotine replacement products (e.g. chewing gum, e-cigarettes)?
  • Food allergies or sensitivities to any of the ingredients contained in the investigational product or any other foodstuff
  • Pregnant, trying to get pregnant or breast feeding
  • Body Mass Index outside of the range 18-35 kg/m2
  • High blood pressure (systolic over 159 mm Hg or diastolic over 99 mm Hg)
  • Currently taking blood pressure medication
  • Currently taking blood thinning medication (e.g. aspirin, warfarin, heparin)
  • Have a respiratory disorder that requires regular medication (Note: participants with asthma who only take their medication occasionally/as required are eligible for this study)
  • Have frequent migraines that require medication (more than or equal to 1 per month)
  • History or current diagnosis of drug/alcohol abuse
  • History of kidney or liver disease, or other severe diseases of the gastrointestinal tract (e.g. iron accumulation, iron utilization disorders, hypercalcaemia, hypercalcaemia), that are likely to interfere with metabolism/absorption/secretion of the product under investigation
  • History of neurological or psychiatric illness (excluding depressive illness and anxiety)
  • History of head trauma
  • Sleep disturbances and/or are taking sleep aid medication
  • Blood disorders (e.g. anaemia, haemophilia, thrombocytosis)
  • Diagnosis of type I or type II diabetes
  • Heart disorder, or vascular illness
  • Current diagnosis of depression and/or anxiety
  • Over- or under-active thyroid
  • Chronic gastrointestinal problems (e.g. Inflammatory Bowel Disease, Irritable Bowel Syndrome, celiac disease)
  • Any known active infections
  • Diagnosed with or may be at risk of having syphilis, hepatitis, the Human T - lymphotropic virus or the Human Immunodeficiency Virus
  • Current or past breast cancer diagnosis and/or a mastectomy
  • Health condition that would prevent fulfilment of the study requirements
  • Currently participating in or in the past 4 weeks participated in other clinical or nutrition intervention studies

研究组 & 干预措施

Olive oil Placebo

Placebo Comparator

3 x 1 g capsules daily Placebo: olive oil

干预措施: EPA-rich (Dietary Supplement)

Olive oil Placebo

Placebo Comparator

3 x 1 g capsules daily Placebo: olive oil

干预措施: DHA-rich (Dietary Supplement)

EPA-rich

Active Comparator

3 x 1 g capsules daily containing a SMEDDS formulation of an EPA-enriched oil totalling 900 mg EPA and 360 mg of DHA

干预措施: Olive Oil Placebo (Dietary Supplement)

EPA-rich

Active Comparator

3 x 1 g capsules daily containing a SMEDDS formulation of an EPA-enriched oil totalling 900 mg EPA and 360 mg of DHA

干预措施: DHA-rich (Dietary Supplement)

DHA-Rich

Active Comparator

3 x 1 g capsules daily containing a SMEDDS formulation of an DHA-enriched oil totalling 900 mg DHA and 270 mg of EPA

干预措施: Olive Oil Placebo (Dietary Supplement)

DHA-Rich

Active Comparator

3 x 1 g capsules daily containing a SMEDDS formulation of an DHA-enriched oil totalling 900 mg DHA and 270 mg of EPA

干预措施: EPA-rich (Dietary Supplement)

结局指标

主要结局

Computerised Location Learning task

时间窗: 26 months

Delayed recall accuracy

Verbal Learning task

时间窗: 26 months

Delayed recall accuracy

次要结局

  • Simple reaction time task(26 months)
  • Computerised Location Learning task(26 months)
  • Verbal Learning task(26 months)
  • Subjective Alertness(26 months)
  • Digit vigilance task(26 months)
  • Peg and Ball/Tower of London task(pre, Mid and post dose measures)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验